Use of the complement inhibitor Coversin to treat HSCT-associated TMA

Use of the complement inhibitor Coversin to treat HSCT-associated TMA

•Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.•Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2017-07, Vol.1 (16), p.1254-1258
Hauptverfasser: Goodship, Timothy H.J., Pinto, Fernando, Weston-Davies, Wynn H., Silva, Juliana, Nishimura, Jun-ichi, Nunn, Miles A., Mackie, Ian, Machin, Samuel J., Palm, Liina, Pryce, Jeremy W., Chiesa, Robert, Amrolia, Persis, Veys, Paul
Format: Artikel
Sprache:eng
Schlagworte:
Exceptional Case Report
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.•Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2016002832